Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic Syndromes

Pediatric Clinics of North America

Volumn 59, Issue 2, 2012, Pages 329-344

  Canna, Scott W ^a   Behrens, Edward M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cytokine storm; Hemophagocytic lymphohistiocytosis; Macrophage activation syndrome; Sepsis

Indexed keywords

ALLERGEN; CORTICOSTEROID; CYCLOSPORIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABNORMAL LABORATORY RESULT; CLINICAL FEATURE; CYTOKINE STORM; CYTOPENIA; CYTOTOXICITY; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; GENE MUTATION; HEMOPHAGOCYTE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MALIGNANCY ASSOCIATED HEMOPHAGOCYTIC SYNDROME; NONHUMAN; REVIEW; RISK FACTOR; X LINKED LYMPHOPROLIFERATIVE SYNDROME;

CYTOKINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MACROPHAGE ACTIVATION SYNDROME;

EID: 84860522672     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.03.002     Document Type: Review

References (55)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20(6):864-874.
2. Goldstein B., Giroir B., Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005, 6(1):2-8.
3. Henter J.I., Horne A., Arico M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48(2):124-131.
4. Behrens E.M., Beukelman T., Paessler M., et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34(5):1133-1138.
5. Kuwata K., Yamada S., Kinuwaki E., et al. Peripheral hemophagocytosis: an early indicator of advanced systemic inflammatory response syndrome/hemophagocytic syndrome. Shock 2006, 25(4):344-350.
6. Imahashi N., Inamoto Y., Ito M., et al. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. Bone Marrow Transplant 2011, 47(3):387-394.
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6(11):823-835.
8. Jyonouchi S. Immunodeficiency Search. 2011. Available at: . Accessed November 1, 2011. http://www.immunodeficiencysearch.com.
9. Pachlopnik Schmid J., Cote M., Menager M.M., et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010, 235(1):10-23.
10. Jordan M.B., Hildeman D., Kappler J., et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004, 104(3):735-743.
11. Lykens J.E., Terrell C.E., Zoller E.E., et al. Perforin is a critical physiologic regulator of T-cell activation. Blood 2011, 118(3):618-626.
12. Crozat K., Hoebe K., Ugolini S., et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med 2007, 204(4):853-863.
13. Krebs P., Crozat K., Popkin D., et al. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 2011, 117(24):6582-6588.
14. Sumegi J., Barnes M.G., Nestheide S.V., et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 2011, 117(15):e151-e160.
15. Pachlopnik Schmid J., Canioni D., Moshous D., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117(5):1522-1529.
16. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002, 44(3):259-272.
17. Castillo L., Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009, 10(3):387-392.
18. Avcin T., Tse S.M., Schneider R., et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006, 148(5):683-686.
19. Sawhney S., Woo P., Murray K.J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001, 85(5):421-426.
20. Hoffman H.M., Brydges S.D. Genetic and molecular basis of inflammasome-mediated disease. J Biol Chem 2011, 286(13):10889-10896.
21. Grom A.A., Villanueva J., Lee S., et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003, 142(3):292-296.
22. Villanueva J., Lee S., Giannini E.H., et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005, 7(1):R30-R37.
23. Vastert S.J., van Wijk R., D'Urbano L.E., et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49(3):441-449.
24. Zhang K., Biroschak J., Glass D.N., et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008, 58(9):2892-2896.
25. Fall N., Barnes M., Thornton S., et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007, 56(11):3793-3804.
26. Yanagimachi M., Naruto T., Miyamae T., et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis. J Rheumatol 2011, 38(4):769-774.
27. Behrens E.M., Canna S.W., Slade K., et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011, 121(6):2264-2277.
28. Guggemoos S., Hangel D., Hamm S., et al. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 2008, 180(1):438-443.
29. Santiago-Raber M.L., Baudino L., Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009, 33(3-4):231-238.
30. Fife M.S., Gutierrez A., Ogilvie E.M., et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther 2006, 8(5):R148.
31. Moller J.C., Paul D., Ganser G., et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol 2010, 28(6):912-918.
32. Maruyama J., Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 2010, 37(5):967-973.
33. Shimizu M., Yokoyama T., Yamada K., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 2010, 49(9):1645-1653.
34. Janka G., Imashuku S., Elinder G., et al. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998, 12(2):435-444.
35. Brown D.E., McCoy M.W., Pilonieta M.C., et al. Chronic murine typhoid fever is a natural model of secondary hemophagocytic lymphohistiocytosis. PLoS One 2010, 5(2):e9441.
36. Zoller E.E., Lykens J.E., Terrell C.E., et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 2011, 208(6):1203-1214.
37. Moore K.W., de Waal Malefyt R., Coffman R.L., et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
38. Doyle T., Bhagani S., Cwynarski K. Haemophagocytic syndrome and HIV. Curr Opin Infect Dis 2009, 22(1):1-6.
39. Veerakul G., Sanpakit K., Tanphaichitr V.S., et al. Secondary hemophagocytic lymphohistiocytosis in children: an analysis of etiology and outcome. J Med Assoc Thai 2002, 85(Suppl 2):S530-S541.
40. Milner J.D., Orekov T., Ward J.M., et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood 2010, 116(14):2476-2483.
41. Ravelli A., Magni-Manzoni S., Pistorio A., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005, 146(5):598-604.
42. Ibarra M.F., Klein-Gitelman M., Morgan E., et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol 2011, 18(4):609-614.
43. Bleesing J., Prada A., Siegel D.M., et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56(3):965-971.
44. Wheeler R.D., Cale C.M., Cetica V., et al. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol 2010, 150(6):727-730.
45. Davi S., Consolaro A., Guseinova D., et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011, 38(4):764-768.
46. Sun S., Rao N.L., Venable J., et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007, 6(4):223-235.
47. Marsh R.A., Jordan M.B., Filipovich A.H. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol 2011, 154(5):556-563.
48. Henter J.I., Samuelsson-Horne A., Arico M., et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100(7):2367-2373.
49. Balamuth N.J., Nichols K.E., Paessler M., et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007, 29(8):569-573.
50. Gupta A.A., Tyrrell P., Valani R., et al. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol 2009, 31(2):81-84.
51. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35.
52. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201(9):1479-1486.
53. Nigrovic P.A., Mannion M., Prince F.H., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63(2):545-555.
54. Behrens E.M., Kreiger P.A., Cherian S., et al. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006, 33(10):2081-2084.
55. Bruck N., Suttorp M., Kabus M., et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011, 17(1):23-27.